ANGLE aims for FDA approval of Parsortix in third quarter following successful meeting

The company is now preparing a De Novo submission for the FDA, a process that allows the regulator to approve medical devices that have no comparative on the market

ANGLE PLC - ANGLE aims for third quarter FDA approval of Parsortix following successful meeting
Parsortix is designed to detect cancer cells in the bloodstream

ANGLE PLC (LON:AGL) has predicted that it will receive regulatory clearance for its Parsortix cancer test by the third quarter of this year following a successful face-to-face meeting with the US Food and Drug Administration (FDA).

The AIM-listed firm said it is now preparing for a full De Novo submission to the FDA, a process that allows the regulator to approve medical devices that have no comparative already on the market.

WATCH: ANGLE aiming for FDA approval of Parsortix in third quarter

Parsortix is a blood test designed to help doctors detect signs of cancer at an early stage, offering a less invasive alternative to tissue biopsies currently used in hospitals.

ANGLE said it is aiming to file its De Novo submission in the first quarter of 2020, with the prospect of regulatory clearance by the third quarter.

While the FDA had requested additional analytical study work, the company said this will be undertaken in parallel with its drafting for the De Novo submission and will not impact the overall timescale of the process.

“We believe that FDA regulatory clearance, considered the gold standard for approval of medical diagnostic systems globally, would further competitively differentiate our Parsortix liquid biopsy system and should lead to an acceleration in commercial adoption of the system in both research and clinical settings", said ANGLE chief executive Andrew Newland.

In a note, analysts at house broker finnCap, which peg the company with a 115p target price, said the successful meeting had “significantly de-risked the regulatory path” for ANGLE, predicting that FDA clearance will be “a watershed moment” that will catalyse more commercialisation and partnership deals.

The shares surged 9.2% to 69p in early trading on Wednesday.

Quick facts: ANGLE PLC

Price: 43.5 GBX

Market: AIM
Market Cap: £93.7 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


ANGLE completes FDA submission for Parsortix system for metastatic breast cancer

ANGLE PLC's (LON:AGL, OTCQX:ANPCY) Andrew Newland talks to Proactive's Katie Pilbeam after announcing the completion of their submission to the FDA for its Parsortix PC1 liquid biopsy for use in women with metastatic breast cancer (MBC). Newland calls the announcement 'a massive day' after...

on 28/9/20

2 min read